Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ASCO relevance

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Apr 29, 2023 6:42pm

160 Views

Post# 35421180

RE:RE:RE:ASCO relevance

"If Pela converts cold cancers to hot and improves survival after immunotherapy, the story is done and the share price will take care of itself. This is a multi-billion $$ indication but many hurdles remain."

It is good to see you back, Geneman. The statement above says it all as to the current state of affairs.

You will recognize some of the old voices here, while a few also post on Yahoo. It appears to be a tiresome and uninformed set of posters on Yahoo for the most part.

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta